JP2022550649A5 - - Google Patents
Info
- Publication number
- JP2022550649A5 JP2022550649A5 JP2021558645A JP2021558645A JP2022550649A5 JP 2022550649 A5 JP2022550649 A5 JP 2022550649A5 JP 2021558645 A JP2021558645 A JP 2021558645A JP 2021558645 A JP2021558645 A JP 2021558645A JP 2022550649 A5 JP2022550649 A5 JP 2022550649A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- epitope
- epitope sequence
- specific
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827018P | 2019-03-30 | 2019-03-30 | |
| US62/827,018 | 2019-03-30 | ||
| PCT/US2020/025796 WO2020205778A1 (en) | 2019-03-30 | 2020-03-30 | Compositions and methods for preparing t cell compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550649A JP2022550649A (ja) | 2022-12-05 |
| JP2022550649A5 true JP2022550649A5 (https=) | 2023-04-07 |
| JP7668226B2 JP7668226B2 (ja) | 2025-04-24 |
Family
ID=72666464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558645A Active JP7668226B2 (ja) | 2019-03-30 | 2020-03-30 | Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220282217A1 (https=) |
| EP (1) | EP3946439A4 (https=) |
| JP (1) | JP7668226B2 (https=) |
| KR (1) | KR20220030208A (https=) |
| CN (1) | CN113939310A (https=) |
| AU (1) | AU2020253368A1 (https=) |
| BR (1) | BR112021019558A2 (https=) |
| CA (1) | CA3132028A1 (https=) |
| IL (1) | IL286776A (https=) |
| MX (1) | MX2021012004A (https=) |
| PH (1) | PH12021552476A1 (https=) |
| SG (1) | SG11202110879PA (https=) |
| TW (1) | TW202102531A (https=) |
| WO (1) | WO2020205778A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3388075T (lt) | 2015-03-27 | 2023-11-10 | Immatics Biotechnologies Gmbh | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003) |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2973548T3 (es) | 2016-12-22 | 2024-06-20 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso |
| CN112584852A (zh) * | 2018-06-19 | 2021-03-30 | 百欧恩泰美国公司 | 新抗原及其用途 |
| US12421557B2 (en) * | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022047325A1 (en) * | 2020-08-31 | 2022-03-03 | The Trustees Of Columbia University In The City Of New York | Targeting of tgm4 to treat prostate cancer |
| US20240000834A1 (en) * | 2020-11-24 | 2024-01-04 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| WO2022115641A2 (en) * | 2020-11-25 | 2022-06-02 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| AU2022238389A1 (en) * | 2021-03-19 | 2023-10-05 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2022226055A1 (en) * | 2021-04-22 | 2022-10-27 | Iogenetics, Llc | Personalized allogeneic immunotherapy |
| US20240287456A1 (en) * | 2021-06-22 | 2024-08-29 | Achilles Therapeutics Uk Limited | A method for producing antigen-specific t cells |
| US20250195659A1 (en) * | 2021-10-15 | 2025-06-19 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| WO2025208068A2 (en) * | 2024-03-29 | 2025-10-02 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1670501A2 (en) * | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| AU2010310468A1 (en) * | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| JP6781403B2 (ja) * | 2013-12-09 | 2020-11-04 | タルゴバックス エーエスエー | ペプチド混合物 |
| EP3097416A2 (en) * | 2014-01-21 | 2016-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for testing t cell priming efficacy in a subject |
| WO2015143558A1 (en) * | 2014-03-27 | 2015-10-01 | British Columbia Cancer Agency Branch | T-cell epitope identification |
| CA3017170C (en) * | 2014-09-17 | 2021-03-23 | The Johns Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| IL297773B2 (en) * | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| BR112017022845A2 (pt) * | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| JP2019513373A (ja) * | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| US11299708B2 (en) * | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| MX2019000180A (es) * | 2016-06-28 | 2019-11-05 | Geneius Biotechnology Inc | Composiciones de células t para la inmunoterapia. |
| AU2017305396A1 (en) * | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| MX2020014243A (es) * | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
-
2020
- 2020-03-30 JP JP2021558645A patent/JP7668226B2/ja active Active
- 2020-03-30 WO PCT/US2020/025796 patent/WO2020205778A1/en not_active Ceased
- 2020-03-30 CN CN202080040129.9A patent/CN113939310A/zh active Pending
- 2020-03-30 BR BR112021019558A patent/BR112021019558A2/pt unknown
- 2020-03-30 SG SG11202110879PA patent/SG11202110879PA/en unknown
- 2020-03-30 US US17/599,468 patent/US20220282217A1/en active Pending
- 2020-03-30 MX MX2021012004A patent/MX2021012004A/es unknown
- 2020-03-30 KR KR1020217034803A patent/KR20220030208A/ko not_active Ceased
- 2020-03-30 AU AU2020253368A patent/AU2020253368A1/en active Pending
- 2020-03-30 EP EP20781922.8A patent/EP3946439A4/en active Pending
- 2020-03-30 CA CA3132028A patent/CA3132028A1/en active Pending
- 2020-03-30 PH PH1/2021/552476A patent/PH12021552476A1/en unknown
- 2020-03-31 TW TW109111088A patent/TW202102531A/zh unknown
-
2021
- 2021-09-29 IL IL286776A patent/IL286776A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550649A5 (https=) | ||
| JP7712970B2 (ja) | ホットスポットを利用した新生抗原の特定 | |
| Sun et al. | MHC class II restricted neoantigen: a promising target in tumor immunotherapy | |
| JP7668742B2 (ja) | Ｍｈｃクラスｉｉモデルによる新生抗原の特定 | |
| CN113631172B (zh) | 用于靶向突变型ras的组合物和方法 | |
| US6440735B1 (en) | Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer | |
| Kronenberger et al. | A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia | |
| Mukherji et al. | Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. | |
| Wysocka et al. | Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 | |
| JP7558151B2 (ja) | Ｔ細胞改変 | |
| JP2017524337A5 (https=) | ||
| Connerotte et al. | Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities | |
| KR20100063060A (ko) | Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물 | |
| Gillespie et al. | The potential of melanoma antigen expression in cancer therapy | |
| Cui et al. | Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells | |
| Holowka et al. | Leishmania-encoded orthologs of macrophage migration inhibitory factor regulate host immunity to promote parasite persistence | |
| WO2017211371A2 (en) | Calr and jak2 vaccine compositions | |
| KR20150046346A (ko) | 항원 특이적 헬퍼 t 세포 리셉터 유전자 | |
| Castro et al. | Transient enhanced IL-2R signaling early during priming rapidly amplifies development of functional CD8+ T effector-memory cells | |
| KR20240026905A (ko) | 림프구의 단일 용기 확장 | |
| Moschella et al. | Gene expression profiling and functional activity of human dendritic cells induced with IFN-α-2b: implications for cancer immunotherapy | |
| US7402307B2 (en) | Method for identifying and killing cancer cells | |
| Ni et al. | Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies | |
| JP2002506633A (ja) | Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法 | |
| Suwabe et al. | Decade-long WT1-specific CTLs induced by WT1 peptide vaccination |